

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Robert L. Gendron, Hélène : Paper No:
Paradis

Serial No. : Group Art Unit:

Filed: : Examiner:

For: INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA
THERAPY

INFORMATION DISCLOSURE STATEMENT

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, Applicant herewith submits certain references which the Patent & Trademark Office may wish to consider in examining the above-identified application. The references are provided below, and are also listed on the attached Form PTO-1449.

OTHER REFERENCES:

1. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning, A Laboratory Manual. 2nd, Cold Spring Harbor Laboratory Press (eds.), New York, 1989.
2. Mullen, J. R., Kayne, P. S., Moerschell, R. P., Tsunasawa, S., Grabskov, M., Colavito Shepanski, M., Grunstein, M., Sherman, F., and Sternglanz, R. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J., 8: 2067-2075, 1989.
3. Ouchida, M., Ohno, T., Fujimura, Y., Rao, V. N., and Reddy, E. S. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene, 11: 1049-1054, 1995.
4. Kovar, H., Aryee, D. N., Jug, G., Henockl, C., Schemper, M., Delattre, O., Thomas, G., and Gadner, H. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ., 7: 429-437, 1996.
5. Gendron, R. L., Tsai, F. Y., Paradis, H., Arceci, R. J. Induction of embryonic vasculogenesis by bFGF and LIF in vitro and in vivo. Dev. Biol., 177: 332-346, 1996.
6. Tanaka, K., Iwakuma, T., Harimaya, K., Sato, H., and Iwamoto, Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest., 99: 239-247, 1997.



26874

PATENT TRADEMARK OFFICE

Serial No.

7. Toretsky, J.A., Connell, Y., Neckers, L., Bhat, N.K. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. *J. Neurooncol.*, 31: 9-16, 1997.
8. May, W. A., Arvand, A., Thompson, A. D., Braun, B. S., Wright, M., and Denny, C. T. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. *Nat. Genet.*, 17: 495-497, 1997.
9. Good, W.V., Paradis, H., Adams, L.C. and Gendron, R.L. Ocular spatial distribution of tubedoen-1 (tbdn-1), a novel acetyltransferase regulated in endothelial cell differentiation. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 9-14, 1998, Fort Lauderdale, Florida.
10. Invited Participant in *Electronic Workshop on Genetic Manipulation in Animals: Advanced Transgenesis and Cloning*. National Institute of Standards and Technology, U.S. Department of Commerce, Advanced Technology Program Website: <http://www.atp.nist.gov/atc/atc-6.htm>. September, 1998. Prospects and hurdles in optimizing the vascular support of engineered tissues.
11. Fizazi, K., Dohollou, N., Blay, J. Y., Guerin, S., Le Cesne, A., Andre, F., Pouillart, P., Tursz, T., and Nguyen, B. B. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. *J. Clin. Oncol.*, 16: 3736-3743, 1998.
12. Liebermann, D. A., and Hoffman, B. MyD genes in negative growth control. *Oncogene*, 17: 3319-3329, 1998.
13. Gewirtz, A. M., Sokol, D. L., and Ratajczak, M. Z. Nucleic acid therapeutics: state of the art and future prospects. *Blood.*, 92: 712-736, 1998.
14. Gendron, R.L., Adams, L.C. and Paradi, H. Tubedown-1, a novel acetyltransferase associated with vascular remodeling. *Experimental Biology '99*. Washington, DC, April, 1999.
15. Palumbo, J. S., and Zwerdling, T. Soft tissue sarcomas of infancy. *Semin. Perinatol.*, 23: 299-309, 1999.
16. Arndt, C. A., and Crist, W. M. Common musculoskeletal tumors of childhood and adolescence. *N. Engl. J. Med.*, 341: 342-352, 1999.
17. Amann, G., Zoubek, A., Salzer-Kuntschik, M., Windhager, R., and Kovar, H. Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. *Hum. Pathol.*, 30: 1058-1064, 1999.
18. Thompson, A. D., Teitell, M. A., Arvand, A., and Denny, C. T. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. *Oncogene*, 18: 5506-5513, 1999.
19. Hahm, K. B., Cho, K., Lee, C., Im, Y. H., Chang, J., Choi, S. G., Sorensen, P. H., Thiele, C. J., and Kim, S. J. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. *Nat. Genet.*, 23: 222-227, 1999.

20. Lin, P. P., Brody, R. I., Hamelin, A. C., Bradner, J. E., Healey, J. H., and Ladanyi, M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. *Cancer Res.*, 59: 1428-1432, 1999.
21. Polevoda, B., Norbeck, J., Takakura, H., Blomberg, A., and Sherman, F. Identification and specificities of N-terminal acetyltransferases from *Saccharomyces cerevisiae*. *EMBO J.*, 18: 6155-6168, 1999.
22. Coffman, F. D., and Studzinski, G. P. Differentiation-related mechanisms which suppress DNA replication. *Exp. Cell. Res.*, 248: 58-73, 1999.
23. Im, S. A., Gomez-Manzano, C., Fueyo, J., Liu, T. J., Ke, L. D., Kim, J. S., Lee, H. Y., Steck, P. A., Kyritsis, A. P., and Yung, W. K. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. *Cancer Res.*, 59: 895-900, 1999.
24. West, D. C. Ewing sarcoma family of tumors. *Curr, Opin, Oncol.*, 12: 323-329, 2000.
25. de Alava, E., and Gerald, W. L. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. *J. Clin. Oncol.*, 18: 204-213, 2000.
26. Im, Y. H., Kim, H. T., Lee, C., Poulin, D., Welford, S., Sorensen, P. H., Denny, C. T., and Kim, S. J. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. *Cancer Res.*, 60: 1536-1540, 2000.
27. Gendron, R. L., Adams, L. C., and Paradis, H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. *Dev. Dyn.*, 218: 300-315, 2000.
28. Bromberg, J., Darnell, J. E. Jr. The role of STATs in transcriptional control and their impact on cellular function. *Oncogene*, 19: 2468-2673, 2000.
29. Yuen, A. R., and Sikic B. I. Clinical studies of antisense therapy in cancer. *Front. Biosci.*, 1: D588-593, 2000.
30. Gewirtz, A. M. Oligonucleotide therapeutics: a step forward. *J. Clin. Oncol.*, 18: 1809-1811, 2000.

We have tried to obtain copies of all the references cited, but were unsuccessful in obtaining copies of references: nos. 1, 12, 15 and 30. Copies of all other listed references are attached. No representation is made or intended that a prior art search has been made or that no better art than the listed is available. It is respectfully requested that the information be considered by the Examiner and made of record in the present application.

Serial No.

The Assistant Commissioner for Patents is authorized to charge any deficiency or credit any overpayment to Frost Brown Todd LLC Deposit Account No. 06-2226.

Karlyn A. Schnapp

Karlyn A. Schnapp, Ph.D.

Registration No. 45,558

FROST BROWN TODD LLC

2200 PNC Center

201 East Fifth Street

Cincinnati, Ohio 45202-4182

April 16, 2001

CERTIFICATE OF MAILING

I hereby certify that a copy of this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231 this 17 day of April, 2001.

Kelley M. Kuhl

CINlibrary/1044419.1